NBTX News & Events

Nanobiotix announced that it has entered into a royalty-based financing agreement with HealthCare Royalty, providing up to $71M in non-dilutive capital. At the closing of the agreement, Nanobiotix will receive an upfront payment of $50M and expects to receive an additional $21M one year post closing subject to reaching certain conditions. Assuming $71M is funded, success-based remuneration to HCRx includes: repayment from a defined portion of royalties on the first $1B of net sales and a portion of certain regulatory and commercial milestone payments, subject to a cap of approximately $124M if repayment is completed by end of 2030, increasing to approximately $178M if repayment occurs thereafter. Following achievement of the Return Cap, a royalty-only tail period will commence, which entitles HCRx to a predefined, reduced share of royalties not to exceed $14.9M per year; the tail period will expire 10 years following the first commercial sale of JNJ-1900 in the U.S. Payment and repayment obligations under both this royalty financing agreement with HCRx and the existing royalty agreement with the European Investment Bank will be furnished through the transfer of receivables from the JNJ-1900 license agreement to a French law trust. Assuming the drawdown of the second tranche one year post closing, this financing extends Nanobiotix cash runway into early 2028 subject to closing of the agreement. This extension of cash runway does not include potential milestone payments from the JNJ-1900 licensing agreement. The company continues to expect to receive the first potential milestone payments related to clinical development in head and neck cancer and lung cancer within this timeframe.

Nanobiotix (NBTX) announced updates to the JNJ-1900 clinical development program. Nanobiotix has completed the transfer of NANORAY-312 sponsorship, initiated in Q3 of 2024, in the majority of regions along with the transfer of full operational control of the Phase 3 clinical trial to Johnson & Johnson (JNJ). Following the transfer and Nanobiotix analysis of the latest information, Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the requisite number of events have been observed and the last patient has been recruited, in 1H2027. Future guidance related to NANORAY-312 and other JNJ-1900-related Johnson & Johnson-sponsored studies will be communicated by Johnson & Johnson. Nanobiotix will continue to provide JNJ-1900 clinical development updates and guidance related to Nanobiotix-sponsored studies as well as studies sponsored by The University of Texas MD Anderson Cancer Center.